MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities

Pedroza-Torres, Abraham; Romero-Córdoba, Sandra; Justo-Garrido, Montserrat; Salido-Guadarrama, Iván; Rodriguez-Bautista, Ruben; Montaño, Sarita; Muñiz-Mendoza, R; Arriaga-Canon, Cristian; Fragoso-Ontiveros, Verónica; Álvarez-Gómez, Rosa María; Hernández, Greco; Herrera, Luis A.

doi:10.3389/fonc.2019.01404

Cited by 68 publications

(51 citation statements)

References 325 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known that miRNAs can intervene in the genesis of neoplastic disease and that their modulation could constitute an important therapeutic opportunity [12][13][14].…”

Section: General Considerations On Microbiota and Mirnasmentioning

confidence: 99%

Interactions between the MicroRNAs and Microbiota in Cancer Development: Roles and Therapeutic Opportunities

Allegra

Musolino

Tonacci

et al. 2020

Cancers

View full text Add to dashboard Cite

The human microbiota is made up of the fungi, bacteria, protozoa and viruses cohabiting within the human body. An altered microbiota can provoke diseases such as cancer. The mechanisms by which a modified microbiota can intervene in the onset and progression of neoplastic diseases are manifold. For instance, these include the effects on the immune system and the onset of obesity. A different mechanism seems to be constituted by the continuous and bidirectional relationships existing between microbiota and miRNAs. MiRNAs emerged as a novel group of small endogenous non-coding RNAs from that control gene expression. Several works seem to confirm the presence of a close connection between microbiota and miRNAs. Although the main literature data concern the correlations between microbiota, miRNAs and colon cancer, several researches have revealed the presence of connections with other types of tumour, including the ovarian tumour, cervical carcinoma, hepatic carcinoma, neoplastic pathologies of the central nervous system and the possible implication of the microbiota-miRNAs system on the response to the treatment of neoplastic pathologies. In this review, we summarise the physiological and pathological functions of the microbiota on cancer onset by governing miRNA production. A better knowledge of the bidirectional relationships existing between microbiota and miRNAs could provide new markers for the diagnosis, staging and monitoring of cancer and seems to be a promising approach for antagomir-guided approaches as therapeutic agents.

show abstract

“…It is well known that miRNAs can intervene in the genesis of neoplastic disease and that their modulation could constitute an important therapeutic opportunity [12][13][14].…”

Section: General Considerations On Microbiota and Mirnasmentioning

confidence: 99%

Interactions between the MicroRNAs and Microbiota in Cancer Development: Roles and Therapeutic Opportunities

Allegra

Musolino

Tonacci

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Xenograft models have also helped to elucidate the role of miRNAs in metabolic reprogramming. Indeed, mounting evidence indicates that also microRNAs (miRNAs), whose aberrant expression represents a hallmark of human HCC, could regulate metabolic reprogramming observed in cancer cells [ 159 ].…”

Section: Microrna and Metabolic Reprogrammingmentioning

confidence: 99%

Animal Models: A Useful Tool to Unveil Metabolic Changes in Hepatocellular Carcinoma

Serra

Columbano

Perra

et al. 2020

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one the most frequent and lethal human cancers. At present, no effective treatment for advanced HCC exist; therefore, the overall prognosis for HCC patients remains dismal. In recent years, a better knowledge of the signaling pathways involved in the regulation of HCC development and progression, has led to the identification of novel potential targets for therapeutic strategies. However, the obtained benefits from current therapeutic options are disappointing. Altered cancer metabolism has become a topic of renewed interest in the last decades, and it has been included among the core hallmarks of cancer. In the light of growing evidence for metabolic reprogramming in cancer, a wide number of experimental animal models have been exploited to study metabolic changes characterizing HCC development and progression and to further expand our knowledge of this tumor. In the present review, we discuss several rodent models of hepatocarcinogenesis, that contributed to elucidate the metabolic profile of HCC and the implications of these changes in modulating the aggressiveness of neoplastic cells. We also highlight the apparently contrasting results stemming from different animal models. Finally, we analyze whether these observations could be exploited to improve current therapeutic strategies for HCC.

show abstract

“…In recent decades, numerous evidence has revealed that miRNAs act as crucial players in the development of various types of human malignancies [ 38 , 39 ]. Accumulating researches have demonstrated that dysregulation of neoplasm-associated miRNAs is involved in the occurrence and development of human HCC [ 23 , 24 , 40 ].…”

Section: Discussionmentioning

confidence: 99%

MicroRNA-183-5p contributes to malignant progression through targeting PDCD4 in human hepatocellular carcinoma

Duan

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) remains one of the most common malignant tumors worldwide. This study aimed to investigate the biological role of microRNA-183-5p (miR-183-5p), a novel tumor-related miRNA, in HCC and illuminate the possible molecular mechanisms. The expression patterns of miR-183-5p in clinical samples were characterized using qPCR analysis. Kaplan-Meier survival curve was applied to evaluate the correlation between miR-183-5p expression and overall survival of HCC patients. Effects of miR-183-5p knockdown on HCC cell proliferation, apoptosis, migration and invasion capabilities were determined via CCK8 assays, flow cytometry, scratch wound healing assays and Transwell invasion assays, respectively. Mouse neoplasm transplantation models were established to assess the effects of miR-183-5p knockdown on tumor growth in vivo. Bioinformatics analysis, dual-luciferase reporter assays and rescue assays were performed for mechanistic researches. Results showed that miR-183-5p was highly expressed in tumorous tissues compared with adjacent normal tissues. Elevated miR-183-5p expression correlated with shorter overall survival of HCC patients. Moreover, miR-183-5p knockdown significantly suppressed proliferation, survival, migration and invasion of HCC cells compared with negative control treatment. Consistently, miR-183-5p knockdown restrained tumor growth in vivo. Furthermore, programmed cell death factor 4 (PDCD4) was identified as a direct target of miR-183-5p. Additionally, PDCD4 down-regulation was observed to abrogate the inhibitory effects of miR-183-5p knockdown on malignant phenotypes of HCC cells. Collectively, our data suggest that miR-183-5p may exert an oncogenic role in HCC through directly targeting PDCD4. The current study may offer some new insights for understanding the role of miR-183-5p in HCC.

show abstract

MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities

Cited by 68 publications

References 325 publications

Interactions between the MicroRNAs and Microbiota in Cancer Development: Roles and Therapeutic Opportunities

Interactions between the MicroRNAs and Microbiota in Cancer Development: Roles and Therapeutic Opportunities

Animal Models: A Useful Tool to Unveil Metabolic Changes in Hepatocellular Carcinoma

MicroRNA-183-5p contributes to malignant progression through targeting PDCD4 in human hepatocellular carcinoma

Contact Info

Product

Resources

About